Physician profile
Kamala D Fields
NPI 1558471995
$8,132.77
in general payments reported to CMS, 2019-2025
29 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,546 · 2022: $1,541 · 2023: $1,388 · 2024: $1,435 · 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,045.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,309.65 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,277.15 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $676.67 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $529.23 | 2022-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $520.07 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Vanda Pharmaceuticals INC. | $471.09 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $423.53 | 2021-2022 | |
| Corium, LLC | $385.17 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $296.44 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $248.98 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $230.78 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $203.56 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $193.58 | 2022-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $187.49 | 2023-2025 | Auvelity |
| Tris Pharma INC | $181.98 | 2021-2025 | Dyanavel Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $175.90 | 2021-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $124.27 | 2022-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $118.71 | 2023-2025 | Xelstrym, Secuado |
| Almatica Pharma LLC | $114.13 | 2021-2025 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $88.92 | 2021-2022 | |
| Lundbeck LLC | $73.18 | 2022-2023 | Rexulti |
| Eisai INC. | $70.62 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $58.95 | 2022-2024 | Subvenite |
| Collegium Pharmaceutical, INC. | $48.78 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $37.98 | 2021 | |
| Indivior INC. | $26.50 | 2024 | Perseris |
| Bausch Health US, LLC | $25.17 | 2022 | |
| Avion Pharmaceuticals | $20.22 | 2023 | Methylphenidate Hydrochloride |
| Merck Sharp & Dohme LLC | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamala Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.